Introduction
============

Acinetobacter species are prevalent agents of nosocomial infections ([@B2]) as they are resistant to environmental conditions and are capable of easily acquiring resistance to antibiotics; and the most commonly isolated species is *Acinetobacter baumannii* ([@B19]).

In the recent years, due to the increase in the use of wide-spectrum antibiotics, *Acinetobacter* species has acquired resistance against these antibiotics. This resistance causes serious problems in providing effective treatment, particularly in intensive care units where antibiotic use is high and interventional procedures (*e.g*., intubation and urinary and intravenous catheters) are frequently performed ([@B4]).

Alternate treatment protocols are being researched as the rate of resistance is increasing. These alternates include regimens using combination of antibiotics and synthesis of new antibiotics. Antimicrobial drug combinations are used to achieve a wider spectrum; they prevent the emergence of drug-resistant mutants, minimize toxicity, and achieve a synergistic effect.

In vitro synergy tests are used to evaluate drug interaction in antibiotic combinations, and include the checkerboard, time-kill, and Etest diffusion methods ([@B17]; [@B11]).

The current study aimed to determine in vitro effects of a combination of sulbactam (SUL) with tigecycline (TGC), meropenem (MP), amikacin (AK), ciprofloxacin (CL), or colistin (CT) against multi-drug resistant nosocomial *A. baumannii* species.

Materials and Methods
=====================

Thirty multi-drug and carbapenem resistant *A. baumannii* species isolated from blood cultures of patients hospitalized in the Ankara Training and Research Hospital between June 2011 and June 2012 were included in the study. Antibiotic susceptibility testing and species-level identification were carried out using conventional methods and the VITEK 2 system (bioMérieux SA, France). Although no current standard definition exists for the term "multi-drug resistance" with respect to *Acinetobacter* sp*.,* resistance to three or more antibiotic classes used in the treatment of Acinetobacter infections is currently accepted as multi-drug resistance. The isolates used in this study were obtained from different clinics and patients hospitalized on different dates, and only one clinical isolate from each patient was included. All isolates were stored at −20 °C in brain-heart medium (Oxoid, UK) containing glycerol until use.

The effects of meropenem, ciprofloxacin, amikacin, tigecycline, and colistin alone, and in combination with sulbactam, against the 30 isolates were studied using the Etest method (bioMérieux, France) in Mueller-Hinton agar medium (Oxoid, UK) according to the manufacturer\'s instructions. The susceptibility breakpoint of the antibiotics used against *A. baumannii* is shown in [Table 1](#t1){ref-type="table"} ([@B13]; [@B14]; [@B6]).

###### [@B6] MIC values of antimicrobials against *A. baumannii* strains

  Antibiotic                                    MIC (μg/mL) breakpoints         
  --------------------------------------------- ------------------------- ----- ------
  Colistin                                      ≤ 2                             ≥ 4
  Ciprofloxacin                                 ≤ 1                       2     ≥ 4
  Meropenem                                     ≤ 4                       8     ≥ 16
  Amikacin                                      ≤ 16                      32    64
  Tigecycline[\*](#TFN1){ref-type="table-fn"}   ≤ 2                       2-8   ≥ 8
  Sulbactam[\*\*](#TFN2){ref-type="table-fn"}   ≤ 4                       8     ≥ 16

Standards determined by FDA for *Enterobacteriaceae*.

Sulbactam values were used according to [@B6] MIC breakpoints for ampicillin-sulbactam.

The fractional inhibitory concentration (FIC) index was used to determine the efficacy of each combination ([@B21]). To determine the FIC index using the Etest, the minimum inhibitory concentration (MIC) of the two antibiotics (denoted as A or B) involved in the combination was first calculated and recorded. To establish the MIC value of the combination, the B strip was placed on the medium and incubated at 37 °C for 1 h. Then, the B strip was removed and the A strip was placed such that it completely overlapped the concentration lines of the B strip. After incubation at 37 °C for 24 h, the intersection of the inhibition zone diameter at the edge of the Etest band was recorded as the MIC value of A in the combination. The same procedure was repeated with each antibiotic and for all combinations. To determine the efficacy of the combination, the FIC index was calculated according to the following equation: $$\begin{array}{l}
{\text{FIC}\operatorname{}\text{A} = \frac{\text{MIC}\operatorname{}\text{of}\operatorname{}\text{drug}\operatorname{}\text{A}\operatorname{}\text{in}\operatorname{}\text{combination}}{\text{MIC}\operatorname{}\text{of}\operatorname{}\text{drug}\operatorname{}\text{A}\operatorname{}\text{alone}}} \\
{\text{FIC}\operatorname{}\text{B} = \frac{\text{MIC}\operatorname{}\text{of}\operatorname{}\text{drug}\operatorname{}\text{B}\operatorname{}\text{in}\operatorname{}\text{combination}}{\text{MIC}\operatorname{}\text{of}\operatorname{}\text{drug}\operatorname{}\text{B}\operatorname{}\text{alone}}} \\
{\Sigma\operatorname{}\text{FIC}\operatorname{}\text{index\ =\ FIC}\operatorname{}\text{A+FIC}\operatorname{}\text{B}.} \\
\end{array}$$

The Σ FIC index values were interpreted as follows: $$\begin{array}{l}
{\Sigma\operatorname{}\text{FIC}\operatorname{}\text{index}\operatorname{} \leq \operatorname{}0.5 = \text{synergistic}} \\
{\Sigma\operatorname{}\text{FIC}\operatorname{}\text{index}\operatorname{} > \operatorname{}0.5\operatorname{}\text{to}\operatorname{}1 = \text{additive}} \\
{\Sigma\operatorname{}\text{FIC}\operatorname{}\text{index}\operatorname{} > \operatorname{}1\operatorname{}\text{to}\operatorname{} < 4 = \text{indifferent}\operatorname{}\text{(ineffective)}\operatorname{}\text{and}} \\
{\Sigma\operatorname{}\text{FIC}\operatorname{}\text{index}\operatorname{} \geq \operatorname{}4\operatorname{} = \text{antagonistic}\operatorname{}\text{interaction}} \\
\end{array}$$

*Pseudomonas aeruginosa* American Type Culture Collection (ATCC) 27853 and *Escherichia coli* ATCC 25922 were used as control species.

Results
=======

[Table 2](#t2){ref-type="table"} shows the MIC values (μg/mL), MIC50 values, MIC90 values (μg/mL), and the susceptibility ratios of the multi-drug and meropenem-resistant isolates.

###### MIC intervals, MIC 50 values, and MIC90 values and susceptibility ratios against *A. baumannii* isolates that were determined with Etest.

  Antibiotics     Bacteria (n = 30)   MIC range (μg/mL)   MIC (μg/mL) 50%   MIC (μg/mL) 90%   Susceptibility ratios                        
  --------------- ------------------- ------------------- ----------------- ----------------- ----------------------- ----- ---- ---- ---- -----
  Colistin        30                  0.16-8              0.032             0.19              30                      100   0    0    0    0
  Meropenem       30                  16-32               32                32                0                       0     0    0    30   100
  Amikacin        30                  1.5-256             96                256               5                       17    8    27   17   56
  Tigecycline     30                  0 75-32             3                 32                14                      47    9    30   7    23
  Sulbactam       30                  2-256               12                32                2                       8     14   46   14   46
  Ciprofloxacin   30                  32-32               32                32                0                       0     0    0    30   100

As shown in the [Table 2](#t2){ref-type="table"}, all of the isolates were resistant to meropenem and ciprofloxacin but susceptible to colistin. Resistance to amikacin (56%) but susceptibility to tigecycline were also high (47%).

A total of 150 Σ FIC values were calculated for the five antibiotic combinations (CT-SUL, MP-SUL, CL-SUL, AK-SUL, TGC-SUL) for all isolates. Our interpretation of the Σ FIC values (synergistic, additive, ineffective (indifferent), and antagonistic) are shown in [Table 3](#t3){ref-type="table"}, and data on the percentage of the interaction are presented in [Table 4](#t4){ref-type="table"}.

###### The list of FIC values for antibiotic combinations against multi-drug resistant *A. baumannii* isolates.

  (n = 30)   CT-SUL   MP-SUL   CL-SUL   AK-SUL   TGC-SUL                               
  ---------- -------- -------- -------- -------- --------- ----- ------- ----- ------- -----
  1          0.0166   S        0.13     S        0.546     ADD   0.148   S     0.09    S
  2          0.123    S        0.156    S        0.697     ADD   0.156   S     0.421   S
  3          0.124    S        0.18     S        0.843     ADD   0.421   S     0.5     S
  4          0.251    S        0.27     S        1.011     ID    0.43    S     0.5     S
  5          0.338    S        0.281    S        1.015     ID    0.5     S     0.5     S
  6          1        ID       0.281    S        1.023     ID    0.523   ADD   0.5     S
  7          1.001    ID       0.39     S        1.024     ID    0.523   ADD   0.5     S
  8          1.005    ID       0.39     S        1.062     ID    0.546   ADD   0.5     S
  9          1.015    ID       0.401    S        1.125     ID    0.546   ADD   0.56    ADD
  10         1.392    ID       0.406    S        1.25      ID    0.593   ADD   0.59    ADD
  11         1.393    ID       0.421    S        1.335     ID    0.729   ADD   0.593   ADD
  12         1.453    ID       0.468    S        1.335     ID    0.781   ADD   0.625   ADD
  13         1.469    ID       0.5      S        1.337     ID    0.781   ADD   0.625   ADD
  14         1.47     ID       0.729    ADD      1.337     ID    0.796   ADD   0.625   ADD
  15         1.48     ID       0.78     ADD      1.338     ID    0.843   ADD   0.687   ADD
  16         1.484    ID       0.796    ADD      1.364     ID    1.01    ID    0.729   ADD
  17         2        ID       0.843    ADD      1.502     ID    1.02    ID    0.833   ADD
  18         2        ID       0.875    ADD      1.505     ID    1.03    ID    0.84    ADD
  19         2        ID       1        ID       1.507     ID    1.031   ID    0.843   ADD
  20         2        ID       1.01     ID       1.511     ID    1.031   ID    0.87    ADD
  21         2        ID       1.03     ID       1.523     ID    1.05    ID    0.916   ADD
  22         2        ID       1.04     ID       1.625     ID    1.166   ID    1       ID
  23         2        ID       1.04     ID       2         ID    1.166   ID    1.031   ID
  24         2.01     ID       1.06     ID       2.003     ID    1.375   ID    1.056   ID
  25         2.95     ID       1.06     ID       2.005     ID    1.375   ID    1.125   ID
  26         2.985    ID       1.125    ID       2.009     ID    1.523   ID    1.25    ID
  27         3        ID       1.52     ID       2.031     ID    1.546   ID    1.341   ID
  28         3.91     ID       1.523    ID       2.039     ID    1.56    ID    1.5     ID
  29         5.7      AG       1.562    ID       2.062     ID    2.04    ID    1.5     ID
  30         7.813    AG       2.02     ID       2500      ID    2.729   ID    1.666   ID

CT: Colistin; MP: Meropenem; AK: Amikacin; TGC: Tigecycline; SUL: Sulbactam; CL: Ciprofloxacin; S: Synergistic; ADD: Additive; ID: Indifferent; AG: Antagonist; ΣFIC: Fractional inhibitory concentration index.

###### Interpretation for interaction results of antibiotic combinations against multi-drug resistant *A. baumannii* isolates.

  Combinations   Observed effect                                
  -------------- ----------------- ---- ---- ---- ---- ---- --- ---
  CT-SUL         5                 17   0    0    23   76   2   7
  MP-SUL         13                43   5    17   12   40   0   0
  CL-SUL         0                 0    3    10   27   90   0   0
  AK-SUL         5                 17   10   33   15   50   0   0
  TGC-SUL        8                 27   13   43   9    30   0   0

CT: Colistin; MP: Meropenem; AK: Amikacin; TGC: Tigecycline; SUL: Sulbactam; CL: Ciprofloxacin.

In the current study, for all drug combinations, the most common interaction observed was indifferent or additive. CL-SUL had the highest indifferent effect at 90% (27/30 isolates), while TGC-SUL had the highest additive effect at 43% (13/30). MP-SUL showed the highest synergistic effect at 43% (13/30) followed by TGC-SUL at 27% (8/30). Antagonistic interference was observed only in the CT-SUL combination (6.66%, 2/30 isolates).

Discussion
==========

The emergence of high antibiotic resistance in *A. baumannii* isolates has impeded the successful treatment of these infections, thus necessitating alternative treatment options. Among the available options, the use of a combination of antibiotics is currently the most preferred treatment approach ([@B8]).

Combination treatment is mainly used to prevent the development of antibiotic resistance and decrease dose-dependent side effects, and to treat polymicrobial infections. Furthermore, it is also used to treat severe infections with high rates of mortality as a combination of antibiotics provides a synergistic effect against the multi-drug-resistant isolates ([@B15]).

While a combination of antimicrobial agents with different mechanisms of action may provide better pharmacokinetic effects or synergy, they may also cause antagonism. The absence of antagonistic interaction among antibiotics has clinical importance, and therefore, many studies have emphasized the need to determine the interactive effects of antibiotic combinations in vitro. A synergistic effect is especially beneficial (is especially beneficial ([@B10]; [@B11]). It is known that the combined administration of carbapenem and aminoglycoside group of antibiotics, the most frequently used combination in the empiric treatment of *Acinetobacter* infections, generally demonstrates an in vitro synergistic effect ([@B16]; [@B3]). However, due to the prevalence of high resistance to both the groups of drugs, as shown in the present study and by previous reports in recent years, colistin appears to be the only viable treatment option. However, as colistin is associated with high nephrotoxicity and neurotoxicity current research is focused on using other treatment options, including use of different antibiotic and drug combinations ([@B9]; [@B7]). Thus, the present study aimed to investigate the in vitro interactions between sulbactam and available antibiotics as possible treatment options.

Sulbactam alone has demonstrated direct antimicrobial activity against *Bacteroides fragilis* and Acinetobacter spp., and has intrinsic bactericidal activity against multi-drug-resistant *Acinetobacter* spp., as it inhibits the penicillin-binding proteins ([@B1]). Tazobactam and clavulanate are less effective compared to sulbactam, but there are no well-documented clinical practice guidelines. In the current study, the MIC50 and MIC90 values of sulbactam were found to be 12 μg/mL and 32 μg/mL, respectively and these values are in agreement with previously reported values. [@B22] have evaluated the efficacy of sulbactam against 195 *A. baumannii* isolates and reported MIC50 and MIC90 values of 8 μg/mL and 128 μg/mL, respectively, while [@B12] have reported MIC50 and MIC90 values of 16 μg/mL and 64 μg/mL, respectively.

A synergistic effect against *A. baumannii* species was observed when sulbactam was combined with ampicillin, carbapenem, or cefoperazone ([@B5]). [@B18] also reported synergistic effects when a combination of meropenem-sulbactam (70%) or colistin-sulbactam (53%) was used against carbapenem, and multi-drug-resistant *A. baumannii* isolates. While [@B15] reported 29% synergy (14/48 isolates) and 58.4% additivity (28/48 isolates) with a sulbactam-meropenem combination against MDR *A. baumannii* isolates using the CB method, conversely, [@B20], using the same method, reported no synergistic interaction when a combination of sulbactam and colistin. We also demonstrated considerable synergistic effects when sulbactam was combined with meropenem (43%, 13/30), tigecycline (27%, 8/30), colistin (17%, 5/30), or amikacin (17%, 5/30), but no synergistic interaction was observed with ciprofloxacin. Importantly, to the best of our knowledge, this is the first report on a synergistic effect between tigecycline and sulbactam, and this result warrants further investigation.

Although [@B20] reported no antagonism with a combination of sulbactam and colistin, we observed a small antagonistic effect (6.66% (2/30) which prompted a reconsideration of the usefulness of this combination and its subsequent rejection.

Although there are several methods for detecting in vitro interactions between combinations of antibiotics, but none is standard. Synergy testing by Etest is an easy-to-perform method that does not obscure the effects of the active drug when used in combination with other drugs ([@B21]). Even though we used sulbactam as the main antibiotic in the Etest, it is not possible to comment on the exact effect of sulbactam as we obtained different results with the various antibiotics tested. While the findings reported here demonstrate similarities with many previous studies in the literature, some differences also exist which could be due to the differences in methodology or resistance patterns of the bacteria tested.

Given the possibility of antibiotic resistance patterns being different for different isolates of *A. baumannii*, any effect observed with a given combination is expected to be strain-specific. This implies that synergy testing for various combinations of antibiotics should be carried out against each patient-based isolate of MDR *A. baumannii*.

Furthermore, as in vitro studies do not accurately represent in vivo conditions, the data obtained from such in vitro studies should be supported by similar results from adequately controlled clinical studies.
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